Effect of Guselkumab (TREMFYA®), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years

被引：0

作者：

Mease, Philip ^{[1
,2
]}

Helliwell, Philip S. ^{[3
]}

Gladman, Dafna ^{[4
]}

Poddubnyy, Denis ^{[5
]}

Baraliakos, Xenofon ^{[6
]}

Chakravarty, Soumya ^{[7
,8
]}

Kollmeier, Alexa ^{[9
]}

Xu, Xie ^{[10
]}

Sheng, Shihong ^{[10
]}

Xu, Stephen ^{[10
]}

Shawi, May ^{[11
]}

van der Heijde, Desiree ^{[12
]}

Deodhar, Atul ^{[13
]}

机构：

[1] Swedish Med Ctr, Providence St Joseph Hlth, Seattle, WA USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[4] Toronto Western Hosp, Schroeder Arthrit Inst, Krembil Res Inst, Toronto, ON, Canada

[5] Charite, Dept Rheumatol, Berlin, Germany

[6] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet Herne, Herne, Germany

[7] Janssen Sci Affairs LLC, Horsham, PA USA

[8] Drexel Univ, Coll Med, Horsham, PA USA

[9] Janssen Res & Dev LLC, La Jolla, CA USA

[10] Janssen Res & Dev LLC, Spring House, PA USA

[11] Janssen Immunol Global Commercial Strategy Org, Toronto, ON, Canada

[12] Leiden Univ, Dept Rheumatol, Med Ctr, Meerssen, Netherlands

[13] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1330

引用

页码：2760 / 2763

页数：4

共 50 条

[1] Effect of Guselkumab a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Mease, Philip
Helliwell, Philip
Gladman, Dafna
Poddubnyy, Denis
Baraliakos, Xenofon
Chakravarty, Soumya
Kollmeier, Alexa
Xu, Lillian
Sheng, Shihong
Xu, Stephen
Shawi, May
van der Heijde, Desiree
Deodhar, Atul
JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 774 - 774
[2] EFFECT OF GUSELKUMAB, A SELECTIVE IL-23P19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PSA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS
Mease, P. J.
Helliwell, P.
Gladman, D. D.
Poddubnyy, D.
Baraliakos, X.
Chakravarty, S. D.
Kollmeier, A.
Xu, X. L.
Sheng, S.
Xu, S.
Shawi, M.
Van der Heijde, D.
Deodhar, A.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 832 - 833
[3] Low Rates of Radiographic Progression with 2 Years of Guselkumab (TREMFYA®), a Selective Inhibitor of the Interleukin-23p19 Subunit: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study of Biologic-naive Patients with Active Psoriatic Arthritis
Mease, Philip
Gottlieb, Alice
McInnes, Iain
Rahman, Proton
Kollmeier, Alexa
Xu, Xie
Jiang, Yusang
Sheng, Shihong
Shawi, May
Chakravarty, Soumya
Lavie, Frederic
van der Heijde, Desiree
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3763 - 3765
[4] Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies
Mease, Philip
Helliwell, Philip
Gladman, Dafna
Poddubnyy, Denis
Baraliakos, Xenofon
Chakravarty, Soumya
Kollmeier, Alexa
Hsia, Elizabeth
Xu, Xie
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Shawi, May
Karyekar, Chetan
Sweet, Kristen
Deodhar, Atul
van der Heijde, Desiree
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[5] LOW RATES OF RADIOGRAPHIC PROGRESSION WITH 2 YEARS OF GUSELKUMAB, A SELECTIVE INHIBITOR OF THE INTERLEUKIN-23P19 SUBUNIT: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Mease, P. J.
Gottlieb, A. B.
Mcinnes, I.
Rahman, P.
Kollmeier, A.
Xu, X. L.
Jiang, Y.
Sheng, S.
Shawi, M.
Chakravarty, S. D.
Lavie, F.
Van der Heijde, D.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 831 - 832
[6] EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
Helliwell, P.
Gladman, D. D.
Poddubnyy, D.
Mease, P. J.
Baraliakos, X.
Kollmeier, A.
Hsia, E. C.
Xu, X. L.
Sheng, S.
Agarwal, P.
Zhou, B.
Chakravarty, D.
Shawi, M.
Karyekar, C.
Deodhar, A.
Van der Heijde, D.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 36 - 37
[7] Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
Mease, Philip J.
Gladman, Dafna D.
Poddubnyy, Denis
Chakravarty, Soumya D.
Shawi, May
Kollmeier, Alexa P.
Xu, Xie L.
Xu, Stephen
Deodhar, Atul
Baraliakos, Xenofon
RHEUMATOLOGY AND THERAPY, 2023, 10 (06) : 1637 - 1653
[8] Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
Philip J. Mease
Dafna D. Gladman
Denis Poddubnyy
Soumya D. Chakravarty
May Shawi
Alexa P. Kollmeier
Xie L. Xu
Stephen Xu
Atul Deodhar
Xenofon Baraliakos
Rheumatology and Therapy, 2023, 10 : 1637 - 1653
[9] Efficacy and safety of Guselkumab through 2 years: Results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis
McInnes, I.
Rahman, P.
Gottlieb, A.
Hsia, E.
Kollmeier, A.
Xu, X.
Sheng, S.
Jiang, Y.
Shawi, M.
Chakravarty, S.
van der Heijde, D.
Mease, P.
EXPERIMENTAL DERMATOLOGY, 2021, 30 : 38 - 38
[10] Efficacy and safety of guselkumab, an anti-IL23 Monoclonal antibody, in patients with active psoriatic arthritis: A phase 2a, randomized, double-blind, placebo-controlled study
Gottlieb, Alice
Deodhar, Atul
Boehncke, Wolf-Henning
Dong, Bin
Wang, Yuhua
Barchuk, William
Hsia, Elizabeth
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB111 - AB111

← 1 2 3 4 5 →